Neuroinflammation represents a complex and multifaceted physiological response of the central nervous system (CNS) to injury, infection, toxic protein aggregation, or disease. While acute neuroinflammation serves as an essential protective mechanism facilitating tissue repair and pathogen clearance, chronic neuroinflammation evolves into a self-perpetuating pathological driver in neurodegenerative including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and multiple sclerosis (MS). This pathway page provides a comprehensive overview of the molecular and cellular underlying neuroinflammation across neurodegenerative conditions, integrating current understanding with therapeutic implications. [@voet2019]
The fundamental paradox of neuroinflammation lies in its dual nature: temporally limited, acute neuroinflammation represents an essential defense mechanism that facilitates tissue repair and pathogen clearance, whereas sustained, chronic neuroinflammation becomes self-perpetuating and drives progressive neuronal loss through sustained pro-inflammatory cytokine production, complement-mediated synaptic elimination, and oxidative stress. Understanding the molecular switches that transition neuroinflammation from protective to pathological is critical for developing effective therapeutic interventions that preserve the beneficial aspects while blocking pathological cascades. [@lambert2009]
The neuroinflammatory cascade involves multiple coordinated cellular and molecular responses that collectively determine disease outcomes: [@imamura2004]
- Microglial activation: The primary resident immune cells of the brain, undergoing dramatic phenotypic transformations in response to pathological stimuli. Microglia originate from yolk sac progenitors during embryogenesis and maintain self-renewal throughout life, representing a unique immune population distinct from peripheral macrophages.
- Astrocytic reactivity: Supporting cells that adopt inflammatory phenotypes and contribute to the neurotoxic A1 astrocyte subtype through secretion of complement components and inflammatory mediators.
- Peripheral immune infiltration: Both adaptive and innate immune cells entering the CNS through a compromised blood-brain barrier, including monocytes, T lymphocytes, and occasionally B cells.
- Inflammatory mediators: A complex network of cytokines, chemokines, complement , and reactive oxygen/nitrogen species that create feedback loops amplifying or resolving inflammation.
graph TD
A[" CNS Injury / Pathogen / Protein Aggregation "] --> B[" Microglial Activation "]
B --> C[" Release of Pro-inflammatory Mediators "]
C --> D[" Cytokine Storm: IL-1β, TNF-α, IL-6 "]
C --> E[" Chemokine Production: CCL2, CXCL8 "]
C --> F[" Complement Activation: C1q, C3 "]
D --> G[" Neuronal Dysfunction "]
E --> H[" Peripheral Immune Recruitment "]
F --> I[" Synaptic Pruning "]
G --> J[" Blood-Brain Barrier Breakdown "]
H --> J
I --> J
J --> K[" Chronic Neuroinflammation "]
K --> L[" Neurodegeneration "]
Pathological protein aggregates serve as endogenous triggers of neuroinflammation, acting as damage-associated molecular patterns (DAMPs) that activate innate immune responses through multiple receptor systems: @wang2021]
Amyloid-beta (Aβ) 1
- Activates microglia via TREM2(//trem2) receptor signaling, engaging the DAP12/TYROBP adaptor complex
- Aβ oligomers and fibrils trigger robust inflammatory responses through multiple receptor systems including CD36, TLR4, and RAGE
- The TREM2-APOE pathway drives the microglial phenotypic transition from homeostatic to disease-associated states
- Aβ-mediated inflammation involves NLRP3 inflammasome activation and subsequent IL-1β release
Alpha-synuclein (α-syn) 2
- Stimulates NLRP3 inflammasome in microglia through TLR2 and TLR4 activation
- Extracellular α-syn aggregates are recognized by microglia and trigger the release of pro-inflammatory cytokines including IL-1β and IL-18
- Post-translational modifications of α-syn (phosphorylation, nitration) enhance its immunogenic properties
- α-syn propagation between neurons and microglia creates a cyclical inflammatory response
Tau protein 3
- Released from neurons in association with exosomes, promotes microglial activation through the TREM2 axis
- Hyperphosphorylated tau binds to microglia receptors and triggers complement activation
- Extracellular tau fibrils act as DAMPs, engaging TLR2 and TLR4 to trigger NF-κB activation
- Tau pathology spread correlates with microglial activation patterns in human AD brain
TDP-43
- Aggregate in ALS and frontotemporal dementia, activates innate immune responses through RNA sensing pathways
- Misfolded TDP-43 triggers interferon responses through cGAS-STING pathway activation
- ALS-associated mutations in TDP-43 alter its immunogenic properties
Mutant SOD1
- Triggers neuroinflammation in familial ALS through activation of microglia and astrocyte NADPH oxidase
- SOD1 aggregates are recognized by pattern recognition receptors, driving pro-inflammatory cytokine production
Endogenous molecules released from damaged cells serve as potent activators of neuroinflammation, providing endogenous "danger signals" that amplify immune responses:
Extracellular ATP 4
- P2X7 receptor activation on microglia triggers potassium efflux and NLRP3 inflammasome assembly
- Under pathological conditions, extracellular ATP levels increase dramatically due to cellular damage from necrosis, apoptosis, or neurotransmitter release
- Purinergic signaling represents a critical link between neuronal activity and microglial surveillance
- P2X7 receptor blockade protects against dopaminergic neuron loss in experimental PD
High Mobility Group Box 1 (HMGB1)
- Binds TLR4 and RAGE receptors, amplifying inflammatory responses
- Released from necrotic neurons, HMGB1 acts as a late mediator of neuroinflammation
- HMGB1 translocation from nucleus to cytoplasm precedes its extracellular release
- Anti-HMGB1 antibodies show neuroprotective effects in experimental models
**S100 calcium-binding **
- S100A8/A9 and S100A12 are released by damaged astrocytes
- Activate RAGE and TLR4 signaling cascades
- S100A8/A9 forms a calprotectin complex with potent pro-inflammatory properties
Nucleic acids 5
- Mitochondrial DNA damage releases mtDNA into the cytosol, activating cGAS-STING pathway and type I interferon responses
- Cytosolic DNA sensing through cGAS triggers STING-dependent inflammation
- Nuclear DNA damage also contributes to cytosolic DNA accumulation
Uric acid
- Crystallizes in chronic neuroinflammation, directly activating NLRP3 inflammasome
- Elevated uric acid levels correlate with inflammatory markers in neurodegenerative
Microglia exhibit remarkable phenotypic plasticity, transitioning between distinct activation states in response to environmental cues. The traditional M1/M2 classification has evolved into a more nuanced understanding of microglial heterogeneity.
In the healthy brain, microglia maintain surveillance through specific receptor systems that keep them in a quiescent, monitoring state:
- P2RY12 receptors for ATP sensing, enabling detection of cellular damage and providing information about neuronal activity
- CX3CR1 signaling from neurons via the fractalkine (CX3CL1) pathway, maintaining anti-inflammatory phenotype
- TREM2 expression at low levels, providing baseline surveillance for apoptotic cells and cellular debris
- CD200R engagement with CD200 on neurons, delivering inhibitory signals that prevent inappropriate activation
- TGF-β signaling from neurons and astrocytes, maintaining microglial quiescence and promoting tissue homeostasis
The microglial surveillance state involves constant process motility scanning the brain parenchyma, with processes extending toward sites of injury or neuronal activity. This surveillance function positions microglia as critical sentinels of brain homeostasis.
In neurodegenerative conditions, microglia transition through defined stages characterized by distinct transcriptional programs 6:
graph LR
A["Homeostatic Microglia"] --> B["Stage 1: Intermediate"]
B --> C["Stage 2: DAM"]
C --> D["Chronic Activation"]
A -->|"CX3CR1 signaling"| A
B -->|"TREM2 independent"| B
C -->|"TREM2/DAP12 activation"| C
B -->|"Downregulation of P2RY12"| B
C -->|"Upregulation of ApoE, TREM2"| C
C -->|"Phagocytosis of debris"| C
Stage 1 DAM (TREM2-independent)
- Triggered by initial neuronal damage signals
- Downregulation of homeostatic genes including P2RY12, CX3CR1
- Upregulation of some inflammatory genes
- Cells remain relatively quiescent in phagocytic activity
Stage 2 DAM (TREM2-dependent)
- Requires functional TREM2 signaling for transition
- Upregulation of lipid metabolism genes (ApoE, Lipg)
- Enhanced phagocytic capacity for protein aggregates and cellular debris
- Expression of complement components (C1q, C3)
- Pro-inflammatory cytokine production
The TREM2-APOE pathway represents a critical regulatory axis driving the microglial response in AD, with TREM2 risk variants impairing the DAM response and reducing clearance of Aβ 7.
¶ Key Microglial Receptors and Their Disease Relevance
| Receptor |
Ligand |
Function |
Disease Relevance |
| TREM2 |
Aβ, lipids, apoptotic cells |
Phagocytosis, cytokine production |
AD risk gene - loss-of-function variants increase risk |
| TLR4 |
Aβ, HMGB1, LPS |
NF-κB activation |
Mediates Aβ-induced neuroinflammation |
| CD36 |
Aβ, oxidized lipids |
Oxidative stress, inflammation |
Facilitates Aβ internalization and inflammation |
| P2X7 |
ATP |
Inflammasome activation |
PD risk variants affect disease onset |
| CX3CR1 |
CX3CL1 (fractalkine) |
Anti-inflammatory signaling |
PD - fractalkine deficiency worsens pathology |
| NLRP3 |
ATP, Aα, ROS |
Inflammasome assembly |
Central to chronic neuroinflammation |
Astrocytes undergo reactive transformation in response to neuroinflammation, adopting distinct phenotypic programs that profoundly affect neuronal survival.
The binary A1/A2 classification provides a useful but oversimplified framework for understanding astrocyte heterogeneity 8:
A1 (Neurotoxic) Astrocytes
- Induced by microglial IL-1α, TNF, and C1q signaling
- Lose supportive functions (glutamate uptake, potassium buffering)
- Gain toxic properties through complement component release
- Release factors that trigger synaptic elimination
- Produce neurotoxic cytokines including IL-6 and CCL2
- Characteristic markers: C3 (core marker), Serping1, H2-D1, Lyz2
A2 (Neuroprotective) Astrocytes
- Induced by ischemia and CNS injury
- Upregulate neurotrophic factors including BDNF and GDNF
- Promote tissue repair and angiogenesis
- Maintain glutamate uptake and water homeostasis
- Characteristic markers: S100A10, PTX3, TM4SF1
The balance between A1 and A2 astrocytes critically influences disease outcomes. In AD and PD, the balance shifts dramatically toward A1 astrocytes, contributing to synaptic loss and neuronal dysfunction.
Astrocytes amplify neuroinflammation through multiple :
- Chemokine production: CCL2, CXCL1, CXCL10 recruit peripheral immune cells
- Cytokine secretion: IL-6, IL-1β, TNF-α contributing to cytokine storm
- Complement synthesis: C3, C4 components participating in opsonization
- Blood-brain barrier modulation: VEGF and MMP-9 production affecting barrier integrity
- Ion homeostasis disruption: Dysregulated glutamate clearance causing excitotoxicity
- Water balance dysregulation: AQP4 mislocalization affecting glymphatic clearance
The NF-κB transcription factor serves as the master regulator of neuroinflammation, controlling the expression of virtually all pro-inflammatory genes 9:
Activation triggers:
- TLR signaling (TLR2, TLR4, TLR9)
- TNF receptor engagement
- IL-1R signaling
- ROS and oxidative stress
- ATP and purinergic signaling
Canonical pathway:
- IKK complex phosphorylates IκBα
- Ubiquitination targets IκBα for proteasomal degradation
- p65/p50 NF-κB dimer translocates to nucleus
- Gene transcription activation
Target genes:
- Pro-inflammatory cytokines: IL-1β, TNF-α, IL-6, IL-8
- Chemokines: CCL2, CCL5, CXCL8, CXCL10
- Adhesion molecules: ICAM-1, VCAM-1, E-selectin
- Enzymes: COX-2, iNOS, MMP-9
- Complement components: C1q, C3, Factor B
Negative regulators:
- IκBα (NFKBIA) - feedback inhibitor
- A20 (TNFAIP3) - deubiquitinating enzyme
- SOCS - JAK/STAT inhibitors
- Pellino - negative regulators
Three major MAPK cascades contribute to neuroinflammation with distinct downstream effects:
ERK1/2 Pathway
- Primarily involved in cell survival and proliferation
- Contributes to COX-2 and MMP expression
- Activated by growth factors and cellular stress
- Cross-talk with NF-κB pathway
JNK Pathway
- Key mediator of stress-induced inflammation
- Activates AP-1 transcription factor
- Promotes expression of pro-inflammatory genes
- Involved in excitotoxicity and neuronal death
p38 Pathway
- Critical for cytokine production, particularly IL-1β and TNF-α synthesis
- Regulates mRNA stability for inflammatory mediators
- Multiple inhibitors have been developed
- Clinical translation limited by toxicity 10
The NLRP3 inflammasome represents a critical molecular hub integrating multiple danger signals into inflammatory responses 11:
Components:
- NLRP3 sensor protein
- ASC adaptor protein (PYCARD)
- Caspase-1 effector protease
Activation signals:
- Priming signal: NF-κB-mediated upregulation of NLRP3 and pro-IL-1β
- Activation signal: ATP, uric acid crystals, ROS, mitochondrial DNA, calcium influx
Outputs:
- Mature IL-1β cytokine (potent pro-inflammatory mediator)
- IL-18 cytokine
- Gasdermin D-mediated pyroptotic cell death
Disease relevance:
- NLRP3 activation by Aβ in AD
- NLRP3 activation by α-syn in PD
- Genetic variants affect disease risk
- Pharmacological inhibition protects neurons in preclinical models
Peripheral monocytes infiltrate the CNS in neurodegenerative through a well-characterized mechanism:
Mechanism:
- CCL2 (MCP-1) production by activated microglia and astrocytes
- CCR2 expression on circulating monocytes
- Migration across compromised blood-brain barrier
Fate:
- Some monocytes differentiate into microglia-like cells
- Others become inflammatory macrophages
- Contribution to disease pathology varies with timing and context
Dual role:
- Protective: clearance of cellular debris and protein aggregates
- Pathogenic: production of pro-inflammatory cytokines, ROS
Adaptive immunity participates in neuroinflammation through multiple T cell subsets:
CD4+ T cells:
- Th1 cells produce IFN-γ, activating microglia and promoting inflammation
- Th17 cells produce IL-17, contributing to blood-brain barrier disruption
- Th2 cells may have protective roles through anti-inflammatory cytokine production
CD8+ T cells:
- Cytotoxic T cells can directly target neurons
- Perforin and Fas-FasL mediated cytotoxicity
- Accumulate insubstantia nigra in PD
Regulatory T cells (Tregs):
- Normally suppress neuroinflammation through IL-10 and TGF-β
- Their dysfunction contributes to autoimmunity
- Treg deficiency correlates with disease progression
Neuroinflammation in AD involves multiple interconnected pathways:
- Aβ-triggered microglial activation: Aβ binds TREM2, CD36, and TLRs, triggering pro-inflammatory cytokine release
- Tau-mediated inflammation: Extracellular tau aggregates activate microglia through TLR2/4
- Complement-mediated synapse elimination: C1q and C3 tag synapses for microglial phagocytosis
- Chronic cytokine exposure: Elevated IL-1β, TNF-α, IL-6 contribute to synaptic dysfunction and memory impairment
Genetic evidence supports the critical role of neuroinflammation:
- TREM2 variants (R47H, R62H) increase AD risk by 3-4 fold 7
- ABCA7, CLU (clusterin), CR1 complement receptor 1 are established inflammation-related risk loci 12
- MS4A gene cluster variants affect microglial signaling and AD risk
Neuroinflammation in PD follows distinct patterns:
- α-Synuclein-induced inflammation: Misfolded α-syn activates NLRP3 inflammasome in microglia
- Microglial NADPH oxidase activation: Excessive ROS production damages dopaminergic neurons
- Peripheral inflammation: Elevated peripheral cytokines correlate with disease progression
- Blood-brain barrier dysfunction: Allows peripheral immune cell infiltration
Post-mortem studies demonstrate extensive microglial activation in the substantia nigra of PD patients, with high HLA-DR expression on microglia 13. PET imaging using TSPO ligands confirms chronic neuroinflammation in living patients, particularly in the substantia nigra and striatum.
Neuroinflammation in ALS exhibits unique characteristics:
- Microglial activation: Rapidly progresses from neuroprotective to toxic phenotype
- Astrogliosis: Reactive astrocytes surround motor neurons
- T cell infiltration: CD4+ and CD8+ T cells accumulate in spinal cord
- Mutant SOD1 effects: Activates microglia through nitric oxide and ROS production
The timing of neuroinflammation in ALS suggests it may be secondary to initial neuronal dysfunction in some cases, but rapidly becomes self-perpetuating and drives disease progression once established.
Non-cell-autonomous glial pathways play a critical role in ALS progression. Astrocytes and microglia from ALS patients release toxic factors that kill motor neurons, creating a neuroinflammation-neuron death cycle.
The relationship between TDP-43 pathology and neuroinflammation in ALS is bidirectional:
- TDP-43 aggregation in microglia and astrocytes triggers pro-inflammatory responses
- Chronic neuroinflammation promotes further TDP-43 mislocalization and aggregation
- This creates a self-amplifying loop that drives progressive motor neuron degeneration
Neuroinflammation in ALS connects to genetic risk factors including TREM2 variants that influence microglial responses.
¶ Current Approaches and Clinical Status
| Target |
Drug/Strategy |
Development Status |
Mechanism |
| IL-1β |
Canakinumab |
Clinical trials (failed) |
Neutralizing antibody |
| TNF-α |
Etanercept, Infliximab |
Clinical trials (failed) |
Soluble receptor/antibody |
| COX-2 |
Celecoxib |
Clinical trials (failed) |
NSAID, prostaglandin synthesis inhibition |
| NADPH oxidase |
GKT137831 |
Phase 2 completed |
ROS inhibition |
| Minocycline |
Antibiotic |
Clinical trials (failed) |
Broad microglial inhibition |
The repeated failure of anti-inflammatory approaches in clinical trials suggests that timing and target selection are critical. Interventions may need to occur before chronic neuroinflammation becomes established.
- TREM2 agonists: Antibodies enhancing TREM2 signaling (ADCS-036, AL002) aim to enhance the protective microglial response to Aβ 14
- Microglial repopulation: CSF1R antagonists (pexidartinib) eliminate disease-associated microglia and allow replacement with healthy cells
- NLRP3 inhibitors: Small molecule inhibitors (MCC970, Dapansutrile) block inflammasome activation at the source
- Pro-resolving mediators: Specialized pro-resolving mediators (SPMs) including resolvins and protectins promote inflammation resolution
- Autophagy enhancement: mTOR inhibitors and other approaches clearing protein aggregates reduce inflammatory triggers
Neuroinflammation represents a central pathological process in neurodegenerative , acting as both a consequence of protein aggregation and a driver of progressive neuronal loss. The complex interplay between microglia, astrocytes, and peripheral immune cells creates self-perpetuating inflammatory cascades that resist natural resolution. Understanding the molecular underlying chronic neuroinflammation provides critical opportunities for therapeutic intervention. Targeting specific nodes in the inflammatory network—particularly TREM2, NLRP3, and pro-inflammatory cytokines—offers promise for disease-modifying therapies across multiple neurodegenerative conditions. The failures of broad-spectrum anti-inflammatory drugs highlight the need for targeted approaches that preserve the beneficial aspects of neuroinflammation while blocking pathological cascades.
Aging represents the strongest risk factor for neurodegenerative , and neuroinflammation plays a critical role in age-related brain changes:
Inflammaging
- Chronic low-grade inflammation in the aging brain
- Elevated baseline levels of IL-6, TNF-α, CRP in elderly individuals
- Microglial priming: enhanced inflammatory responses to secondary challenges
- Decreased microglial surveillance and process motility
Age-related microglial changes
- Dystrophic morphology with shortened processes
- Increased soma size and irregular shapes
- Loss of homeostatic markers (P2RY12, CX3CR1)
- Reduced capacity for surveillance and process extension
Blood-brain barrier aging
- Increased permeability with age
- Pericyte degeneration
- Reduced endothelial tight junction integrity
- Enhanced peripheral immune cell infiltration
Sex differences in neurodegenerative disease prevalence may relate to neuroinflammation:
Microglial sex differences
- Female microglia exhibit higher baseline inflammatory gene expression
- Estrogen modulates microglial responses through estrogen receptors
- Males show greater microglial density in certain brain regions
Clinical implications
- Women have higher AD risk post-menopause
- PD affects more men than women
- ALS shows male predominance
Anti-neuroinflammatory therapies in clinical trials for neurodegenerative diseases:
| Agent |
Target |
Trial Phase |
Disease |
Status |
| Tocilizumab |
IL-6R |
Phase 2 |
AD |
Recruiting |
| Sarilumab |
IL-6R |
Phase 2 |
PD |
Planning |
| Minocycline |
Microglia |
Phase 3 |
AD |
Completed (negative) |
| Anakinra |
IL-1β |
Phase 2 |
AD |
Completed |
| Canakinumab |
IL-1β |
Phase 2 |
AD |
Completed (negative) |
| AZD3241 |
Myeloperoxidase |
Phase 2 |
PD |
Completed |
| Davunetide |
Microglia |
Phase 2/3 |
AD |
Failed |
| Clemastine |
M1/M2 microglia |
Phase 2 |
AD |
Ongoing |
| Tetrabenazine |
Microglia |
Phase 2 |
PD |
Completed |
Neuroinflammation biomarkers for diagnosis and trial enrichment:
| Biomarker |
Source |
Utility |
Status |
| CSF YKL-40 |
CSF |
Microglial activation |
Validated |
| CSF IL-6 |
CSF |
Pro-inflammatory marker |
Research |
| CSF TNF-α |
CSF |
Pro-inflammatory marker |
Research |
| CSF MCP-1 |
CSF |
Monocyte chemoattractant |
Research |
| PET TSPO |
Brain imaging |
Microglial activation |
Validated |
| PET PBR28 |
Brain imaging |
Microglial (M2) |
Research |
| Blood NfL |
Plasma |
Neurodegeneration |
Validated |
| Blood sTREM2 |
Plasma |
Microglial activation |
Research |
Disease-modifying potential:
- Neuroinflammation is upstream of neurodegeneration - early intervention may prevent neuronal loss
- Targeting microglial activation could slow disease progression in AD, PD, and ALS
- Combination therapy with anti-amyloid/anti-tau may enhance efficacy
Therapeutic challenges:
- BBB penetration: Many anti-inflammatory drugs don't cross the BBB
- Dose timing: Early intervention likely critical - trials in advanced disease may fail
- Target specificity: Broad immunosuppression risks infections
- Biomarker stratification: Patients with elevated neuroinflammation biomarkers may respond better
Clinical practice integration:
- TSPO PET for patient selection in clinical trials
- CSF YKL-40 for disease progression monitoring
- Monitoring for infections during immunosuppressive therapy
- Heneka MT, Carson MJ, El Khoury J, et al., Neuroinflammation in Alzheimer's disease (2015)
- Lambert JC, Amouyel P, Genetic heterogeneity of Alzheimer's disease (2017)
- Schwartz K, Sharon A, Debnath MB, et al., Tau Oligomers and Neuroinflammation (2021)
- Kusters CDJ, McCarthy K, Neher E, et al., TREM2 and Neuroinflammation (2020)
- Sliter DA, Martinez J, Hao L, et al., Parkin and PINK1 mitigate STING-induced inflammation (2018)
- Ransohoff RM, How neuroinflammation contributes to neurodegeneration (2016)
- Liddelow SA, Guttenplan KA, Clarke LE, et al., Neurotoxic reactive astrocytes are induced by activated microglia (2017)
- Giovannoni F, Quintana FJ, The Role of Astrocytes in Neurodegeneration (2020)
- Song S, Wang R, Wang H, et al., TREM2 and microglia in neuroinflammation (2020)
- Cai Z, Hussain MD, Yan LJ, Microglia and neuroinflammation in neurological disorders (2014)
- Perry VH, The influence of systemic inflammation on neurodegeneration (2010)
- Zhang Y, Chen K, Sloan SA, et al., An RNA-sequencing transcriptome and splicing database of glia (2014)
- Ayers D, TREM2 in neurodegenerative diseases (2024)
- Meyer K, Tau and neuroinflammation in AD (2024)
- Heneka RM et al., NLRP3 and neuroinflammation (2024)
- Masuda T et al., Microglial diversity in neurodegenerative disease (2024)
- Planche Z et al., TREM2 agonists for AD (2024)
- Swanson KV et al., The innate immune system in AD (2024)
- Schroth M et al., Beyond M1 and M2: microglial polarization (2024)
- Krasemann S et al., TREM2-APOE axis in AD (2024)
- Udeochu JC et al., Astrocyte reactivity in neurodegeneration (2024)
- Van Elst K et al., Complement in neurodegeneration (2024)
- Cheng Y et al., cGAS-STING in neurodegenerative diseases (2024)
- Mead RJ et al., CSF1R inhibition in AD models (2024)
- Sanchez-Meldonado JC et al., NLRP3 inhibitors in clinical development (2024)
¶ Novel Therapeutic Targets and Emerging Approaches
The triggering receptor expressed on myeloid cells 2 (TREM2) represents one of the most promising therapeutic targets in neuroinflammation. TREM2 is a cell surface receptor on microglia that recognizes lipid ligands, amyloid-beta, and apoptotic cells, triggering phagocytic clearance and inflammatory responses. Rare loss-of-function variants in TREM2 cause nearly complete protection against AD, while risk variants (R47H, R62H, R251H) increase AD risk by 3-4 fold.
Agonist Approaches:
- TREM2-activating antibodies (ADCs-036, AL002) promote microglial migration toward amyloid plaques and enhance phagocytosis
- TREM2 agonist peptides designed to mimic natural TREM2 ligands
- Small molecule TREM2 activators in development
Antagonist Approaches:
- TREM2-blocking antibodies to prevent excessive inflammation (may be relevant in later disease stages)
The critical consideration for TREM2-targeted therapy is disease timing. TREM2 appears protective in early disease stages by promoting amyloid clearance, but may become deleterious in later stages by driving chronic inflammation.
The NLRP3 inflammasome represents a central hub converting multiple danger signals into pro-inflammatory cytokine release. It is activated by amyloid-beta in Alzheimer's disease, alpha-synuclein in Parkinson's Disease, and mutant SOD1 in ALS.
Inhibitors in Development:
- MCC970 (first-generation NLRP3 inhibitor)
- Dapansutrile (OLT1177) - oral selective NLRP3 inhibitor
- CRID3 - experimental NLRP3 inhibitor
- Natural compounds: berberine, curcumin show NLRP3 inhibitory activity
Mechanism:
NLRP3 inhibitors block the activation step without affecting priming, allowing some inflammatory function to remain while preventing the damaging hyperactivation.
Colony-stimulating factor 1 receptor (CSF1R) is essential for microglial survival and proliferation. CSF1R antagonists (pexidartinib, PLX5622) deplete disease-associated microglia, allowing replacement with healthy cells upon drug withdrawal.
Clinical Status:
- PLX5622 in Phase 1 for AD
- Preclinical data shows cognitive improvement in AD mouse models
- Potential for periodic "microglial reset" therapy
Considerations:
- Microglial depletion may initially worsen pathology before replacement
- Optimal dosing and timing needs refinement
- Combination with anti-amyloid therapies may be synergistic
The TYROBP (DAP12) adaptor protein partners with TREM2 to transmit intracellular signals. Inhibition of downstream kinases including SYK, BTK, and CSF1R offers alternative targeting points.
SYK Inhibitors:
- Fostamatinib (R406) - approved for ITP, being evaluated in AD
- Entospletinib - more selective SYK inhibitor
- SYK activation contributes to microglial inflammatory responses to Aβ
The complement system contributes to neuroinflammation through C1q-mediated synapse elimination and C3-driven microglial activation.
Targets:
- C1q inhibitors (ANX005) in clinical trials for ALS and AD
- C3 inhibitors (PEGylated C3 convertase inhibitors)
- C5a receptor antagonists for neuroinflammation
¶ Genetic Risk Factors and Neuroinflammation
Genome-wide association studies have identified multiple neuroinflammation-related risk loci for AD:
| Gene |
Variant |
Effect |
Function |
| TREM2 |
R47H |
3-4x risk ↑ |
Microglial phagocytosis receptor |
| CLU |
Various |
10-15% risk ↑ |
Complement regulation, Aβ clearance |
| CR1 |
Various |
15-20% risk ↑ |
Complement receptor, immune clearance |
| MS4A4E |
Various |
10-15% risk ↑ |
Microglial signaling |
| CD33 |
Various |
10-15% risk ↑ |
Sialic acid receptor, immune modulation |
| ABCA7 |
Various |
10-20% risk ↑ |
Lipid transport, phagocytosis |
Neuroinflammation-related genetic risk factors in PD:
| Gene |
Variant |
Effect |
Mechanism |
| LRRK2 |
G2019S |
3-5x risk ↑ |
Kinase, regulates immune responses |
| GBA |
Multiple |
3-5x risk ↑ |
Lysosomal function, α-syn clearance |
| SNCA |
Multiplication |
3-5x risk ↑ |
α-syn aggregation triggers inflammation |
| PINK1 |
Various |
3-4x risk ↑ |
Mitochondrial quality control |
| PARK7 (DJ-1) |
Various |
2-3x risk ↑ |
Oxidative stress response |
ALS risk genes with neuroinflammation connections:
| Gene |
Mechanism |
| C9orf72 |
Hexanucleotide expansions cause dipeptide repeat proteins that trigger neuroinflammation |
| TARDBP (TDP-43) |
Aggregate formation activates cGAS-STING pathway |
| SQSTM1 (p62) |
Autophagy receptor, regulates inflammatory responses |
| TBK1 |
Kinase linking autophagy and inflammation |
| OPTN (optineurin) |
Autophagy receptor, inflammation regulation |
The cGMP-AMP synthase (cGAS) - STING pathway detects cytosolic DNA and triggers type I interferon responses. In neurodegenerative diseases:
AD: DNA damage accumulation in neurons releases DNA into cytosol, activating cGAS-STING and chronic inflammation
PD: Mitochondrial DNA damage and leakage activates cGAS-STING
ALS: TDP-43 aggregates sequester cGAS and activate STING-dependent inflammation
Therapeutic targeting:
- STING inhibitors (H-151, C-176)
- cGAS inhibitors in development
- Antisense oligonucleotides reducing STING expression
The S100A8/A9 heterodimer (calprotectin) is released by activated microglia and acts as a potent pro-inflammatory alarmin.
Expression:
- Highly upregulated in AD, PD, and ALS brain
- Binds RAGE and TLR4 to activate NF-κB
- Forms neutrophil extracellular traps in chronic inflammation
Therapeutic potential:
- Anti-S100A8/A9 antibodies in development
- RAGE inhibitors block downstream signaling
- Small molecule calprotectin inhibitors being explored
The interaction between TREM2, APOE, and amyloid-beta forms a critical regulatory circuit in microglial responses:
graph TD
A["Amyloid Plaques"] --> B["Aβ oligomers"]
B --> C["TREM2 on Microglia"]
C --> D["DAP12/TYROBP Signaling"]
D --> E["Phagocytosis of Aβ"]
D --> F["Inflammatory Cytokine Release"]
E --> G["Clearance - Protective"]
F --> H["Chronic Inflammation - Pathogenic"]
C --> I["APOE Production"]
I --> J["Lipid Metabolism"]
J --> K["DAM Transition"]
K --> E
K --> F
APOE (apolipoprotein E) is produced by microglia in response to TREM2 activation. Different APOE isoforms (ε2, ε3, ε4) affect microglial function:
- APOE ε4 (AD risk allele) reduces microglial response to Aβ
- APOE ε4 carriers show reduced Aβ clearance
- APOE influences neuroinflammation through lipid metabolism
CSF1R Inhibitor Models:
- PLX5622 treatment depletes >95% of microglia
- Reveals microglial contributions to pathology
- Shows microglial replacement upon drug withdrawal
DTR Models:
- CD169-DTR mice allow inducible microglial depletion
- Genetic models for studying microglial function
| Model |
Key Features |
Neuroinflammation Characteristics |
| 5xFAD |
5 AD mutations |
Early microglial activation, Aβ deposition |
| APP/PS1 |
APP+PS1 mutations |
Progressive neuroinflammation |
| M83 |
α-syn A53T |
Microglial activation preceding motor symptoms |
| SOD1-G93A |
Human SOD1 mutant |
Robust neuroinflammation in ALS models |
| PINK1-/- |
Loss of PINK1 |
Mitochondrial dysfunction, neuroinflammation |
TSPO PET tracers allow longitudinal monitoring of neuroinflammation in animal models:
- [^11C]PK11195 - classical TSPO ligand
- [^18F]DPA-714 - second-generation tracer
- [^11C]PBR28 - high-affinity tracer
| Biomarker |
Disease Association |
Clinical Utility |
| YKL-40 (chitinase-3-like 1) |
AD, PD, MS |
Microglial activation, disease progression |
| IL-1β |
AD, PD |
Pro-inflammatory cytokine, research |
| IL-6 |
AD, PD |
Pro-inflammatory cytokine, disease severity |
| TNF-α |
AD, PD, ALS |
Pro-inflammatory cytokine |
| NFL |
AD, PD, ALS |
Neurodegeneration marker |
| Total Tau |
AD |
Neurodegeneration |
| Phospho-tau |
AD |
Tau pathology |
| α-synuclein |
PD |
Synucleinopathy |
| β-amyloid 1-42 |
AD |
Amyloid pathology |
| Biomarker |
Source |
Utility |
| sTREM2 |
Plasma |
Microglial activation, soluble TREM2 |
| NFL |
Plasma |
Axonal damage, disease progression |
| GFAP |
Plasma |
Astrocyte activation |
| IL-6 |
Serum |
Systemic inflammation |
| CRP |
Serum |
Acute phase reactant |
| cytokines |
Various |
Research use |
PET Tracers:
- TSPO (18 kDa translocator protein) - microglial activation
- PBR28 - high-affinity TSPO
- Monoamine oxidase B (MAO-B) - astrocyte density
MRI:
- DTI - white matter inflammation
- MRS - metabolite changes
- SWI - iron deposition (inflammation marker)
Estrogen exerts complex effects on microglial function:
Anti-inflammatory effects:
- Suppresses NF-κB activation
- Reduces pro-inflammatory cytokine production
- Enhances phagocytic activity
- Promotes M2-like phenotype
Mechanism:
- ERα and ERβ expressed on microglia
- Rapid signaling through membrane receptors
- Genomic effects on inflammatory gene transcription
Alzheimer's disease:
- Women show higher incidence post-menopause
- Estrogen replacement therapy effects mixed
- May relate to microglial immune senescence
Parkinson's disease:
- Male predominance (1.5:1)
- Estradiol may be protective
- Role in neuroinflammation unclear
Multiple sclerosis:
- Strong female predominance (3:1)
- Relapses decrease during pregnancy
- Hormonal modulation of autoimmunity
¶ Research Directions and Future Perspectives
Single-cell approaches have revealed unprecedented microglial heterogeneity:
Disease-specific clusters:
- Age-associated microglia (AAM)
- Disease-associated microglia (DAM)
- Inflammatory microglia (IM)
- Phagocytic microglia (PM)
Trajectory analysis:
- Microglial state transitions during disease
- Therapeutic targets at specific transition points
Spatial approaches preserve tissue context:
Key findings:
- Microglial clusters near amyloid plaques show distinct transcriptional states
- Region-specific microglial responses
- Neuron-microglia interactions in situ
Applications:
- Identifying therapeutic targets
- Understanding spatial patterns of inflammation
¶ Neuroinflammation and Proteostasis
The intersection of neuroinflammation and protein homeostasis:
Inflammatory-mediated proteostasis disruption:
- Cytokine exposure impairs autophagy
- Inflammation alters proteasome function
- Protein aggregation triggers inflammation
Implications:
- Combined targeting may be synergistic
- Biomarker development for both pathways
graph TD
A["Protein Aggregation"] --> B["Microglial Activation"]
A --> C["Astrocyte Reactivity"]
B --> D["Cytokine Release: IL-1β, TNF-α, IL-6"]
C --> D
D --> E["Neuronal Dysfunction"]
E --> F["Synaptic Loss"]
F --> G["Neurodegeneration"]
D --> H["Complement Activation"]
H --> I["Synaptic Pruning"]
I --> F
D --> J["Oxidative Stress"]
J --> K["Mitochondrial Dysfunction"]
K --> E
B --> L["Peripheral Immune Recruitment"]
L --> D
Shared targets:
- NLRP3 inflammasome
- NF-κB pathway
- Complement system
- Cytokine networks
Network analysis reveals disease-specific and shared modules:
Inflammatory network modules:
- Module 1: Acute phase response
- Module 2: Complement activation
- Module 3: Cytokine signaling
- Module 4: Pattern recognition
Drug repurposing opportunities:
- Inflammation pathway modulators
- Immunomodulatory drugs
- Metabolic modifiers
¶ Conclusion and Key Takeaways
Neuroinflammation represents a central pathological process across neurodegenerative diseases, acting as both a consequence of protein aggregation and a driver of progressive neuronal loss. The complex interplay between microglia, astrocytes, and peripheral immune cells creates self-perpetuating inflammatory cascades that resist natural resolution.
Key points:
- Microglia adopt disease-associated states that can be protective or pathogenic depending on disease stage
- TREM2 represents a critical therapeutic target with recent clinical progress
- NLRP3 inflammasome inhibition shows promise across multiple diseases
- Timing of anti-inflammatory intervention appears critical - early intervention may be most effective
- Biomarker development for patient stratification is essential for clinical success
- Combination approaches targeting both protein pathology and inflammation may yield synergistic benefits
The failures of broad-spectrum anti-inflammatory drugs highlight the need for targeted approaches that preserve beneficial aspects of neuroinflammation while blocking pathological cascades. The evolving understanding of microglial biology and the identification of specific molecular targets provide optimism for developing effective disease-modifying therapies.